AUTHOR=Xue Ruiqi , Chen Meiwei , Cai Jinhua , Deng Zhenhong , Pan Dong , Liu Xiaohuan , Li Yi , Rong Xiaoming , Li Honghong , Xu Yongteng , Shen Qingyu , Tang Yamei 

TITLE=Blood–Brain Barrier Repair of Bevacizumab and Corticosteroid as Prediction of Clinical Improvement and Relapse Risk in Radiation-Induced Brain Necrosis: A Retrospective Observational Study

JOURNAL=Frontiers in Oncology

VOLUME=11

YEAR=2021

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.720417

DOI=10.3389/fonc.2021.720417

ISSN=2234-943X

ABSTRACT=<sec><title>Background</title><p>Blood–brain barrier (BBB) disruption after endothelial damage is a crucial part of radiation-induced brain necrosis (RN), but little is known of BBB disruption quantification and its role in the evaluation of therapeutic effect and prognosis for drug treatment. In this retrospective study, BBB repair by bevacizumab and corticosteroid and the correlation between BBB permeability and treatment response and relapse were evaluated by dynamic contrast-enhanced MRI (DCE-MRI).</p></sec><sec><title>Methods</title><p>Forty-one patients with RN after radiotherapy for nasopharyngeal carcinoma (NPC) (28 treated with bevacizumab and 13 with corticosteroid), 12 patients with no RN after NPC radiotherapy, and 12 patients with no radiotherapy history were included as RN, non-RN, and normal groups, respectively. DCE-MRI assessed BBB permeability in white matter of bilateral temporal lobe. DCE parameters were compared at baseline among the three groups. DCE parameters after treatment were compared and correlated with RN volume decrease, neurological improvement, and relapse.</p></sec><sec><title>Results</title><p>The extent of BBB leakage at baseline increased from the normal group and non-RN group and to RN necrosis lesions, especially <italic>K</italic><sup>trans</sup> (Kruskal–Wallis test, <italic>P</italic> &lt; 0.001). In the RN group, bevacizumab-induced <italic>K</italic><sup>trans</sup> and <italic>v</italic><sub>e</sub> decrease in radiation necrosis lesions (both <italic>P</italic> &lt; 0.001), while corticosteroid showed no obvious effect on BBB. The treatment response rate of bevacizumab was significantly higher than that of corticosteroid [30/34 (88.2%) <italic>vs</italic>. 10/22 (45.4%), <italic>P</italic> &lt; 0.001]. Spearman analysis showed baseline <italic>K</italic><sup>trans</sup>, <italic>K</italic><sub>ep</sub>, and <italic>v</italic><sub>p</sub> positively correlated with RN volume decrease and improvement of cognition and quality of life in bevacizumab treatment. After a 6-month follow-up for treatment response cases, the relapse rate of bevacizumab and corticosteroid was 10/30 (33.3%) and 2/9 (22.2%), respectively, with no statistical difference. Post-bevacizumab <italic>K</italic><sup>trans</sup> level predicted relapse in 6 months with AUC 0.745 (<italic>P</italic> &lt; 0.05, 95% CI 0.546–0.943, sensitivity = 0.800, specificity = 0.631).</p></sec><sec><title>Conclusions</title><p>Bevacizumab improved BBB leakage in RN necrosis. DCE parameters may be useful to predict therapeutic effect and relapse after bevacizumab.</p></sec>